glp 1 and heart failure European Society of Cardiology/Heart Association position paper on the role safety of new glucose‐lowering drugs in patients with failure - Seferović - 2020 Treatment of High-Risk Patients with

PMID: 16352683 | doi:10.1210/jc.2005-1536 Alba M et al

Important safety considerations include: Increased hypoglycaemia risk when used with insulin or sulfonylureas (dose adjustments of these medications may be needed) Potential worsening of diabetic retinopathy with rapid improvement in blood glucose control, particularly with semaglutide Need for monitoring in patients with pre-existing retinopathy The MHRA continues to monitor the safety profile of these agents

It is recommended taking 1 tablet daily for at least 3 months for the best results

It is not a drug, supplement, food, cosmetic, or medical device, and it is not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any condition